Patents by Inventor Rachel Jane Roth Flach

Rachel Jane Roth Flach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BCKDK INHIBITORS AND/OR DEGRADERS
    Publication number: 20230167080
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.
    Type: Application
    Filed: November 30, 2022
    Publication date: June 1, 2023
    Applicant: Pfizer Inc.
    Inventors: Leanne Marie BUZON, Kimberly O'Keefe CAMERON, Kevin Francis DEBOYACE, Kevin James FILIPSKI, David Andrew GRIFFITH, Bethany Lyn KORMOS, Shenping LIU, Luis Angel MARTINEZ ALSINA, Matthew Richard REESE, Rachel Jane ROTH FLACH, Yuan ZHANG
  • BCKDK inhibitors
    Patent number: 11542270
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 3, 2023
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
    Publication number: 20220363673
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Application
    Filed: June 24, 2020
    Publication date: November 17, 2022
    Applicant: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Christopher Ryan Butler, Kevin James Filipski, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Kiyoyuki Omoto, Brian Raymer, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • BCKDK inhibitors
    Patent number: 11059833
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: July 13, 2021
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • BCKDK INHIBITORS
    Publication number: 20210087204
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Application
    Filed: October 23, 2020
    Publication date: March 25, 2021
    Applicant: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • BCKDK INHIBITORS
    Publication number: 20210024536
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Application
    Filed: June 26, 2020
    Publication date: January 28, 2021
    Applicant: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang